

Product Data Sheet

Cas No.:	2256084-03-2	Cat. No:	PL08936
Product Name:	Sugemalimab		
Product synonym:	舒格利单抗		
Chemical name:	Sugemalimab		
MF:	-	FW:	-
Purity:	-	Batch No.:	-
Storage:			
λmax:	-	Formulation:	-
Solubility :			
SMILES :	-		
InChI Code:	-		
InChI Key:			
WARNING This product is not for human or veterinary use.			

Product Description

Sugemalimab 是一种完整的人全长抗程序性死亡配体 1 (PD-L1) 免疫球蛋白 G4 (IgG4) 单克隆抗体 (mAb)。Sugemalimab 显示出抗癌活性，可用于非小细胞肺癌的研究。

生物活性	Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research.
IC50 & Target[1][2]	PD-L1
体外研究(In Vitro)	Sugemalimab (CS1001) specifically binds to PD-L1, competitively blocks the binding of human PD-L1 with PD-1 and CD80, and effectively induces CD4+T lymphocyte proliferation and enhances the production of interferon- γ and interleukin-2. Sugemalimab employs IgG4 isotype and lacks antibody-dependent cellular mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	Sugemalimab (CS1001) significantly inhibits tumor growth in the subcutaneous MC38-hPD-L1 murine colon carcinoma (murine MC38 cells expressing human PD-L1) in human PD-1 knock-in mouse model. Sugemalimab not only enhances the cytotoxic T cell/regulatory T cell ratio, but also significantly upregulates M1 macrophage and down-regulated MDSC (myeloid-derived suppressor cells) population in D-1/PD-L1 dual knock-in mice implanted with MC38-hPD-L1 tumor. has not independently confirmed the accuracy of these methods. They are for reference only.
包装储存	Please store the product under the recommended conditions in the Certificate of Analysis.